ORIGINAL_ARTICLE
Radiotherapy Delivery for Women with Early Breast Cancer
https://mejc.sums.ac.ir/article_41905_98572faf7076f9c1975aae849d600b5c.pdf
2010-07-01
105
108
John
Yarnold
john.yarnold@icr.ac.uk
1
Radiotherapy Department, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, UK
LEAD_AUTHOR
ORIGINAL_ARTICLE
Evaluation of Intravenous Magnesium Supplementation as Prophylaxis for Cisplatin-induced Hypomagnesemia
Background: We assessed the effects of cisplatin-based chemotherapy, magnesium supplementation, probable contributory factors such as cisplatin cumulative dose and dose per cycle on serum magnesium levels.Methods: In this prospective randomized study, serum magnesium levels of 59 newly diagnosed adult patients receiving cisplatin-based chemotherapy were studied. The patients were randomly allocated to receive magnesium supplementation at a dose of 5 g IV per cycle (n=31) or to a control group (n=28). Serum magnesium levels <1.8 mg/dL were considered to indicate hypomagnesemia.Results: The decrease in mean magnesium levels with continuing chemotherapy courses was significant in both groups with a more prominent decrease in the control group. In courses 4 and 5, mean magnesium levels were significantly higher among those who received magnesium supplementation than in the control group. Thirty patients (50.8%) had at least one incident of hypomagnesemia after beginning chemotherapy. All hypomagnesemia incidents were mild (mean 1.69, range; 1.52-1.79 mg/dL). Hypomagnesemia was more frequent in the control group (38.7% vs. 60.7%, P=0.09). Although age and sex had no significant effect on the incidence of hypomagnesemia, more hypomagnesemia incidents were observed in patients who received cisplatin in a single loading dose than in those who received the drug in divided doses for each cycle (71.4% % vs. 42.9%, P=0.056).Conclusion: Magnesium supplementation at a dose of 5 g per cycle partially compensated for cisplatin- induced magnesium loss. Monitoring magnesium levels and magnesium supplementation is warranted, especially for those undergoing protracted courses of cisplatin-based chemotherapy. Patients who receive the drug in a single loading dose might be more prone to magnesium loss.
https://mejc.sums.ac.ir/article_41904_ffeed70c399ee57df9e79ae95ecd70c7.pdf
2010-07-01
109
114
Kazem
Anvari
anvarik@mums.ac.ir
1
Department of Radiotherapy and Oncology, Cancer Research Center, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
Mehdi
Sielanian Toussi
silanianm@mums.ac.ir
2
Department of Radiotherapy and Oncology, Cancer Research Center, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
Marjaneh
Mirsadraee
marjanemirsadraee@yahoo.com
3
Department of Radiotherapy and Oncology, Cancer Research Center, Omid Hospital, Mashhad University of Medical Sciences, Mashhad, Iran
AUTHOR
ORIGINAL_ARTICLE
Impact of Scattered Radiation on Testosterone Deficiency and Male Hypogonadism in Rectal Cancer Treated with External Beam Pelvic Irradiation
Background: We performed a prospective study to evaluate the effects of pelvic irradiation on FSH, LH and testosterone levels in male patients with rectal adenocarcinoma. Our aim was to compare the level of male sex hormones in peripheral blood serum before and after pelvic irradiation.Methods: The eligible participants were 40 men with rectal adenocarcinoma who underwent pelvic radiotherapy as part of their treatment for primary tumor, either before or after surgery. All patients received a 50-Gy radiation dose to the pelvis, 2 Gy per fraction, five days per week. Blood was sampled three times during the study: once before radiation, at the end of the radiation course and 4 to 6 weeks after radiotherapy.Results: Median age of the patients was 58 years (range 18-82). The mean testis dose of radiation per fraction in all 40 patients was 16.3 cGy with a standard deviation of 15.22 (range 5.5-64.8). Serum levels of FSH revealed a significant increase from 7.5 ± 1.7 IU/L (before treatment) to 20.9 ± 17.8 IU/L [end of radiotherapy (P<0.001)] and 24.1 ± 20.5 IU/L [4 to 6 weeks after radiotherapy (P<0.001)]. Serum LH levels were significantly elevated from 8.04 ± 1.2 IU/L before radiation to 11.6 ± 11.5 IU/L at the end of radiotherapy (P<0.001) and 12.5 ± 9.9 IU/L 4 to 6 weeks after the final course of radiotherapy (P<0.001). There was a decrease in serum testosterone from 5.3±2.1 ng/mL before radiation to 4.2 ± 1.9 ng/mL at the end of radiotherapy (P=0.004) and 4.5 ± 2 ng/mL 4 to 6 weeks after radiotherapy (P=0.035). No significant correlation was seen between age and differences in sex hormones (LH, P=0.605; FSH, P=0.380; testosterone, P=0.161).Conclusion: There was a significant change in serum levels of male sex hormones after pelvic irradiation for rectal cancer (total dose, 50 Gy) that indicates considerable testicular damage under these circumstances. Thus, it seems logical to use techniques that reduce the radiation dose to the testicles and to consider the benefits of hormone replacement therapy as well as semen cryopreservation for high-risk patients who desire children in the future.
https://mejc.sums.ac.ir/article_41908_ac370aae25c9f01b66af20d7b5b342e1.pdf
2010-07-01
115
122
Niloofar
Ahmadloo
ahmadloon@gmail.com
1
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Farzad
Bidouei
2
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Mohammad Amin
Mosleh-Shirazi
amosleh@sums.ac.ir
3
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Gholam Hossein
Omrani
4
Endocrinology and Metabolism Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Shapour
Omidvari
omidvari@sums.ac.ir
5
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Ahmad
Mosalaei
mosalaa@gmail.com
6
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Mansour
Ansari
ansarim_1999@yahoo.com
7
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Halimeh Khatoon
Ahmadi
8
Radiation Oncology Department, Namazi Hospital, Shiraz, Iran
AUTHOR
Mohammad
Mohammadianpanah
mohpanah@gmail.com
9
Radiation Oncology Department, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
ORIGINAL_ARTICLE
Calculation of Changes in Radiation Exposure due to Prostate Displacement in Permanent Prostate Brachytherapy
Background: Limited studies are available on the calculation of radiation exposure and its associated risks for people in contact with patients who have been treated with permanent prostate brachytherapy. In this study the changes in the radiation exposure were calculated in different stages of the bladder fullness in prostate seed brachytherapy.Methods:Magnetic resonance images of three patients with full and empty bladders and different prostate sizes (32-71 mL; mean 54.6 mL) were used for Monte-Carlo dose calculations. Dose rate to skin for each patient was calculated using MCNP4c, MCNPX.Results: There were no significant differences between dose distribution in the skin relative to the changes in the prostate position due to bladder filling (P=0.05).Conclusion: Our results showed a negligible change in radiation exposure around the patient due to prostate displacement after bladder filling.
https://mejc.sums.ac.ir/article_41909_b130e0c386d9d46c4d014dc0a3ef3d08.pdf
2010-07-01
123
128
Milad
Baradaran-Ghahfarokhi
milad_bgh@yahoo.com
1
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
LEAD_AUTHOR
Mohammad Amin
Mosleh-Shirazi
amosleh@sums.ac.ir
2
Physics Unit, Department of Radiotherapy and Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Reza
Faghihi
faghihir@shirazu.ac.ir
3
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
AUTHOR
Mohammad Hadi
Bagheri
mosleh_amin@hotmail.com
4
Department of Radiology and Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Kamal
Hadad
kamal.hadad@gmail.com
5
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
AUTHOR
Ali
Alavian-Ghavanini
ghavanini1@gmail.com
6
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
AUTHOR
Zahra
Siavashpour
7
Mechanical Engineering Department, School of Engineering, Shiraz University, Shiraz, Iran
AUTHOR
Hamed
Kasayi
8
Medical Radiation Engineering Department, School of Engineering, Shahid Beheshti University, Tehran, Iran
AUTHOR
ORIGINAL_ARTICLE
Telomerase Activity in Chicken Embryo Fibroblast Cell Cultures Infected with Marek's Disease Virus
Background: Telomerase is a ribonucleoprotein, which adds telomeric repeats onto the 3’ end of existing telomers at the end of chromosomes in eukaryotes. One hypothesis states that telomere length may function as a mitotic clock, therefore expression of telomerase activity in cancer cells may be a necessary and essential step for tumor development and progression.Methods: The detectability of telomerase activity in chicken embryo fibroblast (CEF) cells infected with different passages of Marek's disease virus (MDV) was tested with the TRAPEZE® telomerase detection kit at passages 14 (P14), P80/1 and P120 for the Woodland strain, and passage 9 (P9) for the MPF57 strain.Results: The results showed increased telomerase activity in MDV Woodlands strain at P14 and MPF57 strain at P9.Conclusion: Our results suggest that MDV-transformed cells at low passage are a suitable system for the study of telomerases in tumor development and for testing telomerase-inhibiting drugs.
https://mejc.sums.ac.ir/article_41910_5f84fd4f3ae35b8ffd2f094afb829061.pdf
2010-07-01
129
133
Mohammad
Motamedifar
motamedm@sums.ac.ir
1
Department of Bacteriology and Virology, Shiraz HIV/AIDS Research Center (SHARC), Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Gregory
Tannock
2
Department of Applied Biology and Biotechnology, RMIT University, Melbourne, Australia
AUTHOR
ORIGINAL_ARTICLE
Cutaneous Metastases from Different Internal Malignancies in Egypt
Background: Cutaneous metastasis is defined as the spread of malignant cells from a primary malignancy to the skin. Generally, cutaneous involvement from internal malignancies is uncommon. No reports have focused on the cutaneous metastasis profiles in Egypt or the Middle Eastern population. In this study, we seek to determine the rates at which different internal malignancies give rise to cutaneous metastases upon first diagnosis of the primary tumor.Methods: Patients with internal malignancies who attended the South Egypt Cancer Institute from January 2004 through May 2010 were examined and followed to identify cutaneous metastases, which were confirmed by biopsy and histological evaluation.Results: Among 2208 cases of internal malignancies, 48 cases of cutaneous metastases were detected. The clinical profiles were similar to those from western and Asian countries, although the frequencies of primary tumors differed. Most commonly in Egypt breast cancer and urinary bladder cancers were seen.Conclusion: The risk of skin metastases depends largely on the characteristics of tumor cells, which are similar among different groups.
https://mejc.sums.ac.ir/article_41906_4691acfd8d7afc33d18c2a8044ebef8f.pdf
2010-07-01
135
139
Amen
Zaky
amenzaky74@yahoo.com
1
Departments of Medical Oncology, Radiotherapy and Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
LEAD_AUTHOR
Mostafa
El-Wanis
2
Departments of Medical Oncology, Radiotherapy and Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
AUTHOR
Hisham
Hamza
3
Departments of Medical Oncology, Radiotherapy and Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assuit, Egypt
AUTHOR
Hisham
Abdel-Hafez
4
Dermatology Department, Faculty of Medicine, Assuit University,Assuit, Egypt
AUTHOR
Nagwa
Abdel-Azim
5
Dermatology Department, Faculty of Medicine, Assuit University,Assuit, Egypt
AUTHOR
ORIGINAL_ARTICLE
Synovial Sarcoma of the Palatine Tonsil: Report of Two Cases and Review of the Literature
Here, we describe young men with synovial sarcoma in the palatine tonsil, who presented with a 3-4 month history of progressive sore throat, tonsillar ulcerative mass and bleeding. Clinical and radiological examinations revealed that the tumors arose from the palatine tonsil and extended to the parapharyngeal space. Both tumors were too advanced to remove completely; therefore, they underwent surgical debulking during tonsillectomy and partial pharyngectomy. Histopathological and immunohistochem- ical studies confirmed the diagnosis of synovial sarcoma of the palatine tonsil. Despite postoperative radiotherapy and systemic chemotherapy, they relapsed 18 and 22 months later. The first patient died from unresectable local recurrent disease three years after primary diagnosis, and the second patient is alive after 36 months, but suffers from unresectable locoregional recurrent disease and is receiving palliative chemotherapy and supportive care.
https://mejc.sums.ac.ir/article_41903_0419504d45aff8969551b9d80c4f6ad6.pdf
2010-07-01
141
146
Bijan
Khademi
khademib@yahoo.com
1
Cancer Research Center and Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Hajar
Bahranifard
2
Cancer Research Center and Department of Otolaryngology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Mohammad
Mohammadianpanah
mohpanah@gmail.com
3
Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Mohammad Javad
Ashraf
mjashraf46@yahoo.com
4
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Negar
Azarpira
negarazarpira@gmail.com
5
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Mehdi
Dehghani
mehdi_dehghani6@yahoo.com
6
Department of Hematology Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
ORIGINAL_ARTICLE
Adult Mesoblastic Nephroma: A Case Report
Mesoblastic nephroma is a rare entity in adulthood. We report a case of mesoblastic nephroma in a 35-year-old woman who presented with left flank pain. Computed tomography images favored a soft tissue mass in the upper pole of the left kidney. The lesion was excised and sent for pathological analysis. Pathological and immunohisto- chemical studies favored a diagnosis of mesoblastic nephroma.
https://mejc.sums.ac.ir/article_41907_55c854362beeeace4af2f6297192e83a.pdf
2010-07-01
147
150
Mehdi
Salehipour
salehipourmehdi@yahoo.com
1
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
LEAD_AUTHOR
Reza
Mohammadian
reza_mohammadian@yahoo.com
2
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Sara
Pakbaz
3
Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Vahid
Emadmarvasti
4
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Ghasem
Sadeghi
5
Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR